| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer EH Romond, EA Perez, J Bryant, VJ Suman, CE Geyer Jr, NE Davidson, ... New England journal of medicine 353 (16), 1673-1684, 2005 | 7279 | 2005 |
| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ... The Lancet 384 (9938), 164-172, 2014 | 4808 | 2014 |
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer J Baselga, J Cortés, SB Kim, SA Im, R Hegg, YH Im, L Roman, JL Pedrini, ... New England Journal of Medicine 366 (2), 109-119, 2012 | 3240 | 2012 |
| Congestive heart failure in patients treated with doxorubicin A retrospective analysis of three trials SM Swain, FS Whaley, MS Ewer Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 2909 | 2003 |
| Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer SM Swain, J Baselga, SB Kim, J Ro, V Semiglazov, M Campone, ... New England journal of medicine 372 (8), 724-734, 2015 | 2467 | 2015 |
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 379 (9814), 432-444, 2012 | 2329 | 2012 |
| Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women … DLW Kwong, P McGale, C Taylor, C Correa, D Cutter, F Duane, M Ewertz, ... The Lancet, 2014 | 2016 | 2014 |
| Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 J Baselga, SM Swain Nature Reviews Cancer 9 (7), 463-475, 2009 | 1473 | 2009 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo … SM Swain, SB Kim, J Cortés, J Ro, V Semiglazov, M Campone, E Ciruelos, ... The lancet oncology 14 (6), 461-471, 2013 | 1183 | 2013 |
| Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG … EA Perez, EH Romond, VJ Suman, JH Jeong, G Sledge, CE Geyer Jr, ... Journal of clinical oncology 32 (33), 3744-3752, 2014 | 1172 | 2014 |
| Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ... The Lancet Oncology 19 (1), 27-39, 2018 | 1033 | 2018 |
| Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in … E Tan-Chiu, G Yothers, E Romond, CE Geyer Jr, M Ewer, D Keefe, ... Journal of Clinical Oncology 23 (31), 7811-7819, 2005 | 1009 | 2005 |
| 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3) F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ... The Breast 31, 244-259, 2017 | 939 | 2017 |
| Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS IL Wapnir, JJ Dignam, B Fisher, EP Mamounas, SJ Anderson, TB Julian, ... Journal of the National Cancer Institute 103 (6), 478-488, 2011 | 912 | 2011 |
| Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials C Taylor, C Correa, FK Duane, MC Aznar, SJ Anderson, J Bergh, ... Journal of Clinical Oncology 35 (15), 1641-1649, 2017 | 802 | 2017 |
| Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. SM Swain, FS Whaley, MC Gerber, S Weisberg, M York, D Spicer, ... Journal of clinical oncology 15 (4), 1318-1332, 1997 | 792 | 1997 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 783 | 2020 |
| Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells KA West, J Brognard, AS Clark, IR Linnoila, X Yang, SM Swain, C Harris, ... The Journal of clinical investigation 111 (1), 81-90, 2003 | 742 | 2003 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 701 | 2017 |
| Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 386 (10001), 1353-1361, 2015 | 698 | 2015 |